Exploring the role of iodine in obesity, diabetes, and other metabolic conditions
March 21, 2024 / Metabolic Syndrome, Iodine, Insulin
Iodine plays a critical role in metabolic health, affecting obesity, diabetes, and metabolic syndrome (MetS). Research shows that both too little and too much iodine can lead to health issues, emphasizing the need for balanced iodine intake. Its benefits include antioxidant, anti-inflammatory effects, and improved insulin sensitivity. Ensuring appropriate iodine levels is vital for metabolic regulation and preventing related disorders.
Metabolic syndrome increases the risk of all types of cancer, study finds
March 22, 2024 / Metabolic Syndrome / Cancer Risk / Chronic Inflammation
Metabolic syndrome increases cancer risk by 30%, especially for breast, endometrial, kidney, and liver cancers. A study highlights the link between the syndrome’s severity, chronic inflammation, and elevated cancer risk, emphasizing the need for its management to lower potential cancer development.
Middle-age obesity is caused by changes in brain structure
March 18, 2024 / Obesity / Heart Disease / Diabetes / Chronic Conditions
Middle-age obesity is a growing concern worldwide, linked to a myriad of health issues such as diabetes, heart disease, and other chronic conditions. Traditional understanding attributes this weight gain to a decrease in metabolism due to aging.
Efficacy and safety of tirzepatide in overweight and obese individuals with type 1 diabetes
March 22, 2024 / Tirzepatide / Type 1 Diabetes / Weight Loss / Obesity
Tirzepatide shows promise for overweight/obese type 1 diabetes patients, leading to significant weight loss, improved glucose control, and reduced insulin doses in a year-long study.
FDA Approves Rezdiffra, the First Drug for NASH, a Form of Fatty Liver Disease
March 24, 2024 / FDA Approval / Rezdiffra / NASH / Liver / Obesity
The FDA approved Rezdiffra for NASH, making it the first drug for this severe liver condition linked to obesity, type 2 diabetes, and metabolic syndrome. Rezdiffra improves liver scarring in patients with moderate to advanced scarring.
A sweet-tangy solution to obesity: Evaluating the efficacy and mechanistic insights of stingless bee honey and its potential clinical applications
March 21, 2024 / Honey / Obesity / Metabolic Health
Stingless bee honey shows potential as an anti-obesity agent, with animal studies indicating weight loss and improved metabolic health. Further research is needed to confirm these effects in humans.
‘Ozempic babies’ are surprising women taking weight loss drugs. Doctors think they know why
March 21, 2024 / Ozempic / Mounjaro / Women’s Health / Weight Loss
Women on weight loss drugs like Ozempic and Mounjaro are experiencing unexpected pregnancies, possibly due to weight loss correcting hormonal imbalances or the drugs reducing birth control efficacy. Experts warn against using these for pregnancy.
Bone homeostasis discovery could lead to new obesity and osteoporosis treatments
March 21, 2024 / Obesity / Bone Density / Metabolism
Researchers at The University of Hong Kong discovered that the hormone secretin regulates energy metabolism and bone density in mice. This breakthrough could lead to new treatments for obesity and osteoporosis by targeting the brain.
Exploring the role of iodine in obesity, diabetes, and other metabolic conditions
March 21, 2024 / Iodine / Metabolic Health / Thyroid / Obesity / Diabetes
A study highlights iodine’s role in metabolic health, affecting conditions like obesity and diabetes through its impact on thyroid hormones and energy metabolism. Understanding iodine’s metabolic effects could lead to better dietary guidelines.
Aspirin cuts liver fat in trial
March 21, 2024 / Aspirin / Liver / MASLD / Clinical Trial / Cancer
A clinical trial found that low-dose aspirin reduced liver fat content by 10.2% in patients with MASLD, offering a potential low-cost treatment option to prevent cirrhosis or liver cancer associated with this common liver disease.
Severe fatty liver disease patients see benefits with lanifibranor
March 25, 2024 / MASH / Type 2 Diabetes / Liver Disease
Lanifibranor showed promise in reducing blood sugar levels and liver disease signs in metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes patients, according to interim results from the Phase 2 LEGEND clinical trial.
Positive Phase 2 Data Shows Benefit of Lanifibranor with Empagliflozin for MASH, T2D
March 20, 2024 / MASH / NASH / Type 2 Diabetes
The phase 2 LEGEND trial showed that lanifibranor, combined with empagliflozin, significantly reduced HbA1c and improved liver and metabolic markers in patients with MASH/NASH and type 2 diabetes.
InSphero and PharmaNest Unveil a Promising Tool for MASH Drug Discovery
March 22, 2024 / MASH / Drug Discovery / 3D Model
InSphero and PharmaNest developed a novel method for quantifying fibrosis in MASH drug discovery, utilizing a 3D model and digital pathology. This approach overcomes previous limitations and demonstrates the potential of new tools in evaluating antifibrotic treatments.
Impact of metabolic syndrome on bone mineral density in men over 50 and postmenopausal women according to U.S. survey results
March 22, 2024 / Metabolic Syndrome / Women’s Health
Research using NHANES data found Metabolic Syndrome (MetS) positively correlated with bone mineral density (BMD) in men over 50 and postmenopausal women, suggesting gender moderates the impact of MetS on BMD.
Indian wearables startup raises $35m to help users track metabolic health
March 20, 2024 / Wearable Devices / Metabolic Health / Healthtech
Ultrahuman, an Indian healthtech startup, raised $35 million to expand its wearable devices and services for tracking metabolic health. Its products, including the Ultrahuman Ring Air, are available globally and aim to surpass $100 million in revenue by 2024.
Tobacco exposure before birth and in childhood can increase type 2 diabetes risk
March 20, 2024 / Type 2 Diabetes / Adolescence
Early tobacco exposure, either prenatally or during childhood and adolescence, significantly correlates with an increased risk of developing type 2 diabetes later in life, as demonstrated by UK Biobank data presented at an American Heart Association session.
NHS doctor warns ‘hidden’ fat could lead to diabetes, stroke and heart disease
March 21, 2024 / Diabetes / Heart Disease
Research indicates smokers have higher visceral fat levels, which is linked to serious health issues like diabetes, stroke, and heart disease. This “hidden” fat, surrounding internal organs, can be present even in slim individuals, raising major health concerns.
Diet, lifestyle and gut microbiota composition among Malaysian women with gestational diabetes mellitus: a prospective cohort study
March 22, 2024 / Gut Microbiota / Diet / Lifestyle
This study explored the relationship between gut microbiota, diet, and lifestyle in Malaysian Malay women with gestational diabetes mellitus (GDM). It found that GDM is linked with changes in gut microbiota composition, elevated body weight, glucose levels, poor sleep, less physical activity, and dietary differences. This research underscores the complexity of GDM and the potential for targeted dietary and lifestyle interventions.
C-peptide Level in Patients With Uncontrolled Type 2 Diabetes Mellitus on Oral Anti-diabetic Drugs
March 24, 2024 / Type 2 Diabetes / Anti-diabetic Drugs
This study investigates the prevalence of beta-cell dysfunction, indicated by low serum C-peptide levels, in long-term type 2 diabetes mellitus patients on oral anti-diabetic drugs in India. It found a significant correlation between low C-peptide levels and poor glycemic control, suggesting a need for insulin assessment in patients with longstanding diabetes. The study supports using SGLT-2 inhibitors over other drugs as an adjunct to metformin therapy.
Prevalence of diabetic kidney disease and the associated factors among patients with type 2 diabetes in a multi-ethnic Asian country
March 25, 2024 / Type 2 Diabetes / Kidney Disease
In Malaysia, 56.7% of patients with type 2 diabetes have diabetic kidney disease (DKD), with risk factors including age, Malay ethnicity, and poor glycemic control. Addressing modifiable factors could help manage DKD and prevent end-stage kidney disease progression.
Inflammation in pancreas among risk factors for this cancer with CF
March 25, 2024 / Hypertension / Cystic Fibrosis / Pancreatic Cancer / Diabetes
A study found that people with cystic fibrosis (CF) and a history of pancreatic inflammation, diabetes, hypertension, and high cholesterol have a higher risk of developing pancreatic cancer. These findings support the need for efficient risk prediction models for pancreatic cancer screening in CF patients, highlighting the prevalence of known cancer risk factors such as smoking, alcohol consumption, and obesity in this group.
Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE
March 22, 2024 / Relief Therapeutics / Eton Pharmaceuticals
Relief Therapeutics has licensed its PKU GOLIKE products to Eton Pharmaceuticals for U.S. commercialization. The deal includes an upfront payment, potential sales milestones, and royalties. PKU GOLIKE targets the estimated $100 million U.S. market for PKU medical formulas.
Nemaline Myopathy in a Hypotonic Neonate: Diagnostic Approach for Early Detection and Management
March 25, 2024 / Genetic Testing / Neonatal Hypotonia
This study details the diagnostic approach and management of nemaline myopathy (NM) in a hypotonic neonate. It emphasizes the importance of excluding life-threatening conditions and utilizing rapid genetic testing to avoid invasive procedures, shorten hospital stays, and guide management. The case of a four-week-old girl highlights the complex interplay of symptoms leading to NM diagnosis, showcasing the effectiveness of a multidisciplinary approach in managing such rare genetic diseases.
Where Will Amicus Therapeutics, Inc. (FOLD) Stock Go Next After It Has Fallen 0.51% in a Week?
March 20, 2024 /Amicus Therapeutics / Stock Decline
Amicus Therapeutics, Inc. (FOLD) stock has seen a slight decline of 0.51% over the past week, despite receiving a Bullish rating from InvestorsObserver’s Sentiment Indicator. This reflects short-term technical analysis rather than the company’s fundamentals, highlighting investor sentiment and recent volume trends as key indicators of the stock’s direction.
New HOPE for kids with Krabbe disease
March 20, 2024 / Krabbe Disease / Early Detection
Krabbe disease, a rare but treatable condition, has been added to the national Newborn Screening (NBS) guideline as of January 30, 2024. This inclusion aims to detect the disease early in infants for timely, disease-altering treatment.